Minerva Neurosciences, INC Schedule 13G passive stakes

Balyasny Asset Management and affiliated entities have disclosed beneficial ownership of 9.99% of Minerva Neurosciences' common stock, holding 4,654,212 shares.

Farallon Capital Management and associated entities have disclosed beneficial ownership of 9.7% of Minerva Neurosciences' common stock, primarily through convertible preferred stock and warrants.

Federated Hermes, Inc. and associated entities have filed a Schedule 13G, reporting beneficial ownership of 17.17% of Minerva Neurosciences, Inc. common stock as of June 30, 2026.

Janus Henderson Group plc has reported beneficial ownership of 9.9% of Minerva Neurosciences, Inc. common stock, holding 4,307,759 shares.

Balyasny Asset Management and its affiliates have reported a 9.99% beneficial ownership stake in Minerva Neurosciences, Inc. common stock.

Adage Capital Management, L.P. and its principals have reported a 6.35% beneficial ownership stake in Minerva Neurosciences, Inc. as of December 31, 2025.

Farallon Capital Management and its affiliates updated their beneficial ownership in Minerva Neurosciences, Inc., reflecting personnel changes and a 9.99% aggregate stake.

Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. have disclosed passive beneficial ownership stakes of 9.99% each in Minerva Neurosciences, Inc. common stock.

Farallon Capital and its affiliated entities have reported a combined beneficial ownership of 9.99% in Minerva Neurosciences, Inc., including common stock and convertible preferred stock warrants.

Federated Hermes and related entities have filed a Schedule 13G, disclosing a 19.86% passive beneficial ownership stake in Minerva Neurosciences, Inc. after converting from a Schedule 13D.